Will Medicare drug-price negotiation be expanded to 30+ drugs before 2028?
Peer-to-Peer Order Book
Live- A participant offers to buy or sell a contract at a price they choose.
- Another participant takes the opposite side.
- The exchange matches the orders and holds the collateral.
- Correct contracts settle at $1.00 · incorrect at $0.00.
- Fees are shown before any order is submitted.
What this market asks
In plain language: forecasters are estimating the probability that the outcome in the question actually happens by the deadline. The market currently prices 36% YES / 64% NO. Resolution is mechanical — it depends only on the criteria and sources below, not on opinions, headlines, or who "deserves" to win the argument.
- ▸ Demonstration polling shows 76% support for expanded negotiation, including 64% of Republicans.
- ▸ First-round negotiated prices published in 2026 came in 22% below list, strengthening the case.
- ▸ Budget scorers credit expansion with deficit savings, easing reconciliation math.
- ▸ Pharmaceutical litigation over the existing program is still pending in two circuits.
- ▸ Expansion requires a legislative vehicle; no reconciliation bill is currently planned before 2028.
- ▸ Industry has proposed voluntary rebates as a compromise to freeze the cap.
Resolution criteria
Resolves YES if legislation raising the annual cap on Medicare-negotiated drugs to at least 30 is enacted before January 1, 2028, per Congress.gov. CMS administrative selections under existing caps do not count.
- Any participant may flag a resolution within 72 hours with cited evidence.
- Trading pauses; positions freeze at last price while flags are reviewed.
- An independent resolution council (rotating, disclosed members) rules within 14 days using only the stated sources.
- Rulings are published with full written reasoning; credits settle after publication.
Related on Quorly
Discussion · 198 comments
LiveThe NO side is about timelines, not merits. Even if the outcome eventually happens, the deadline in the criteria is doing a lot of work.
Committee calendar update: relevant action is now scheduled. In backtests of this market class, a scheduled action adds ~6 points to YES within a week.
Fading the crowd here. "Pharmaceutical litigation over the existing program is still pending in two circuits." That blocker has killed similar outcomes repeatedly — I have fair value near 26%.
YES at 36% is the value side. When the resolution source is this mechanical, momentum in the underlying process matters more than commentary.
The NO side is about timelines, not merits. Even if the outcome eventually happens, the deadline in the criteria is doing a lot of work.
YES at 36% is the value side. When the resolution source is this mechanical, momentum in the underlying process matters more than commentary.
Following this one closely. The resolution criteria are unusually clean, which is why participation is this high (6.9K forecasters).
Committee calendar update: relevant action is now scheduled. In backtests of this market class, a scheduled action adds ~6 points to YES within a week.
The market is underpricing this. Base rates on comparable outcomes put fair value closer to 44%. Holding YES at 31 entry.
Committee calendar update: relevant action is now scheduled. In backtests of this market class, a scheduled action adds ~6 points to YES within a week.
The market is underpricing this. Base rates on comparable outcomes put fair value closer to 44%. Holding YES at 31 entry.
This market pairs well with the related Pulse question — the gap between public sentiment and market probability is the interesting signal here.